1-(3,5-Dimethylpyridin-2-yl)piperazine → HCID 71252033, 화합물

HRID 2411612노트

반응식

HRID 2411612 반응식
[O:1]=[S:2]1(=[O:18])[CH2:6][CH2:5][CH2:4][N:3]1[C:7]1[CH:16]=[CH:15][C:10]([C:11]([O:13]C)=O)=[C:9]([CH3:17])[N:8]=1.[CH3:19][C:20]1[C:21]([N:27]2[CH2:32][CH2:31][NH:30][CH2:29][CH2:28]2)=[N:22][CH:23]=[C:24]([CH3:26])[CH:25]=1>>[CH3:19][C:20]1[C:21]([N:27]2[CH2:28][CH2:29][N:30]([C:11]([C:10]3[C:9]([CH3:17])=[N:8][C:7]([N:3]4[CH2:4][CH2:5][CH2:6][S:2]4(=[O:1])=[O:18])=[CH:16][CH:15]=3)=[O:13])[CH2:31][CH2:32]2)=[N:22][CH:23]=[C:24]([CH3:26])[CH:25]=1

참가 물질

3

반응물 2

HCID 584844961-(3,5-Dimethylpyridin-2-yl)piperazineHCID 71252256HCID 71252256, 화합물

생성물 1

HCID 71252033HCID 71252033, 화합물수율 67.2%

실험 절차

Using methyl 6-(1,1-dioxo-1λ6-isothiazolidin-2-yl)-2-methylnicotinate (220 mg) described in Preparation Example 37 and 1-(3,5-dimethylpyridin-2-yl)piperazine (186 mg) described in Preparation Example 79 and by the reaction and treatment in the same manner as in Example 109, the title compound (235 mg) was obtained.

후처리

  1. customdescribed in Preparation Example 79 and by the reaction and treatment in the same manner as in Example 109

출처 및 근거

ORD 기록
ord-200a0e8bc4e949c3901168e8c3121671
출처 데이터셋
uspto-grants-2014_08
특허 번호
US08816079B2

반응 노트

불러오는 중…